ORTX - Orchard Therapeutics plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
15.25
+0.85 (+5.90%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close14.40
Open14.59
Bid12.10 x 800
Ask16.00 x 1000
Day's Range14.50 - 15.25
52 Week Range8.65 - 19.24
Volume102,791
Avg. Volume45,650
Market Cap179.849M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-13.69
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est24.50
Trade prices are not sourced from all markets
  • GlobeNewswire9 days ago

    Orchard Therapeutics Announces Acceptance of Late-Breaking Abstracts of OTL-101 for ADA-SCID and OTL-102 for X-CGD at the 2019 Transplantation and Cellular Therapy Meetings of ASBMT and CIBMTR

    BOSTON and LONDON, Feb. 06, 2019 -- Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients.

  • GlobeNewswire24 days ago

    Orchard Announces Publication by San Raffaele-Telethon Institute for Gene Therapy of OTL-300 Clinical Data for the Treatment of Transfusion-Dependent Beta-Thalassemia in Nature Medicine

    Orchard Therapeutics (ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced that the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) has published encouraging results from a clinical trial of OTL-300, an autologous ex vivo lentiviral gene therapy program being studied in individuals with transfusion-dependent beta-thalassemia. “Orchard recognizes the pioneering work of researchers and clinicians from SR-Tiget that has led to this peer-reviewed publication of promising clinical data for the treatment of transfusion-dependent beta-thalassemia patients in Nature Medicine,” said Andrea Spezzi, M.D., chief medical officer of Orchard Therapeutics.

  • GlobeNewswirelast month

    Orchard Therapeutics Highlights Recent Accomplishments and 2019 Strategic Priorities as a Global Leader in Gene Therapy

    BOSTON and LONDON, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today summarized recent accomplishments and 2019 strategic priorities in conjunction with its attendance at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco. Mark Rothera, president and chief executive officer, will present a business overview outlining the company’s progress as a global leader in gene therapy on Wednesday, January 9, 2019 at 3:00 p.m. PT that will be webcast at ir.orchard-tx.com. “2018 was a momentous year for Orchard, marked by the success of our acquisition and integration of GSK’s rare disease ex-vivo gene therapy portfolio, initial scaling of our manufacturing capabilities and completion of our initial public offering,” said Mr. Rothera.

  • GlobeNewswirelast month

    Orchard Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference on January 9, 2019

    BOSTON and LONDON, Jan. 02, 2019 -- Orchard Therapeutics (NASDAQ: ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients.

  • 2019 biotech preview: Money is pouring into the Bay Area and so is Big Pharma
    American City Business Journals2 months ago

    2019 biotech preview: Money is pouring into the Bay Area and so is Big Pharma

    Person to watch Jennifer Cook The 25-year Genentech veteran — most recently in charge of clinical operations — after a year on the job is leading early cancer diagnostics company Grail toward a potential $500 million IPO. Grail is also launching a 50,000-person study to see if its technology can detect multiple cancer types earlier, particularly lung cancer. Technology to watch AI / ML From Daphne Koller’s Insitro to Alice Zhang’s Verge Genomics Inc., artificial intelligence and machine learning are moving beyond hype to real-time lab use.

  • Benzinga2 months ago

    Positive Data From Orchard Therapeutics Turns Goldman Sachs Bullish

    Orchard Therapeutics PLC – ADR (NASDAQ: ORTX ), a rare disease gene therapy company, recently went public, offering 14.29 million shares at $14 each. The shares were listed on the Nasdaq Oct. 31 and ended ...

  • Targeting 'bubble baby' disease, this gene therapy company is planting a flag in the East Bay
    American City Business Journals2 months ago

    Targeting 'bubble baby' disease, this gene therapy company is planting a flag in the East Bay

    Orchard Therapeutics is tackling "bubble baby" disease and other rare genetic conditions with gene therapy.

  • GlobeNewswire2 months ago

    Orchard Therapeutics Appoints Industry Veteran Alicia Secor to its Board of Directors

    BOSTON and LONDON, Dec. 07, 2018 (GLOBE NEWSWIRE) -- Orchard Therapeutics (ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced the appointment of Alicia Secor to its board of directors. Ms. Secor brings more than 25 years of life sciences leadership and commercial product expertise with a particular focus in rare disease and other areas of unmet need, most recently serving as president and chief executive officer at Juniper Pharmaceuticals, Inc.

  • GlobeNewswire2 months ago

    Donald B. Kohn, MD, Orchard Therapeutics Scientific Advisory Board Member, Presents Clinical Proof-of-Concept Data for OTL-102 Gene Therapy for the Treatment of Patients with X-CGD at the Presidential Symposium at the 2018 ASH Annual Meeting

    BOSTON and LONDON, Dec. 05, 2018 (GLOBE NEWSWIRE) -- Orchard Therapeutics (ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through innovative gene therapies, today announced that Scientific Advisory Board Member, Donald B. Kohn, MD, presented clinical proof-of-concept data from an ongoing academic clinical trial evaluating OTL-102 for the treatment of X-Linked Chronic Granulomatous Disease (X-CGD) during the Presidential Symposium at the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition on December 4, 2018. X-CGD is a life-threatening inherited immunodeficiency disorder which is caused by a genetic mutation that results in the inability of neutrophils to effectively kill bacterial and fungal pathogens.

  • Benzinga4 months ago

    IPO Outlook For The Week: Banks And Biotechs

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . IPO dates are expected, not confirmed, at time of publication. BankFlorida (BFL) will issue 6.2 million shares between ...